HeartMate® II continuous-flow left ventricular assist system.

Published

Journal Article (Review)

Left ventricular assist devices (LVADs) have emerged as a beneficial therapeutic strategy proven to improve the morbidity and mortality of patients with advanced heart failure. Continuous-flow rotary LVADs have been developed in the hopes of delivering circulatory support in a more durable manner with fewer device-related complications. The HeartMate(®) II continuous-flow left ventricular assist system (LVAS; Thoratec Corporation, Pleasanton, CA, USA) has become the standard of care for heart failure patients who require long-term mechanical circulatory support. The efficacy of the HeartMate II has been demonstrated in patients where temporary support with an LVAD is needed until a suitable donor organ can be found for transplant (termed 'bridge to transplantation'), as well as for terminally-ill heart failure patients who are not candidates for transplant ('destination therapy'). When directly compared with a pulsatile LVAD, the implantation of a HeartMate II LVAS resulted in an overall improvement in survival with a reduction in the number of device-related complications and adverse events. The purpose of this article is threefold: to describe the history of the development of continuous-flow LVADs; to describe the technology of the HeartMate II; and, finally, to review the clinical outcomes in patients who have been implanted with the device.

Full Text

Duke Authors

Cited Authors

  • Sheikh, FH; Russell, SD

Published Date

  • January 2011

Published In

Volume / Issue

  • 8 / 1

Start / End Page

  • 11 - 21

PubMed ID

  • 21158536

Pubmed Central ID

  • 21158536

Electronic International Standard Serial Number (EISSN)

  • 1745-2422

Digital Object Identifier (DOI)

  • 10.1586/erd.10.77

Language

  • eng

Conference Location

  • England